Survivorship and Patients Perspective
Weiping Liu, Mingzi Yang, Meng Wu, Lingyan Ping, Yuqin Song, Jun Zhu
Peking University Cancer Hospital & Institute
Background: Little studies focused on the relationship between hepatitis B virus (HBV) infection and Hodgkin lymphoma (HL). This study was to evaluate the impact of HBV infection on the treatment outcome and survival of HL patients.
Methods: Clinical data of HL patients treated with ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine) between January 2002 and January 2018 were collected. Patients with HBV infection [hepatitis B surface antigen (HBsAg)-positive] were reviewed. To minimize the impact of confounding factors, patients without HBV infection [HBsAg-negative and anti-hepatitis B core antigen (anti-HBc)-negative) were matched 1:2 by age and sex.
Results: The incidence of HBV infection in HL patients was 5.6% (18/324). There was no significant difference in clinical characteristics between the two groups. The complete remission rates were similar in patients with or without HBV infection (77.8% vs. 77.8%, P = 1.000). After 30 months of follow-up, the 3-year progression-free survival rate in patients with HBV infection was lower than in those without HBV infection (77% vs. 96%, P = 0.042). However, no statistically significant difference in 3-year overall survival was observed between the two groups (88% vs. 92%, P = 0.589).
Conclusions: HBV infection did not appear to affect the clinical outcome and prognosis of HL patients.